ELMD
Electromed, Inc.
ELMD's fundamentals are strong and it looks cheap: trading at 18x earnings, below its usual 32x.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ELMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
ELMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ELMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $24.97 | — |
| Cheap | 25x | $34.57 | +38% |
| Fair | 31x | $43.15 | +73% |
| Expensive | 44x | $60.28 | +141% |
Historical ranges are pointers, not guarantees.
ELMD's PE is in its cheap range at 18x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ELMD Forward outlook
There aren't enough analyst estimates for ELMD to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ELMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.37 | +46% |
| Q2 2026 | $1.30 | +53% |
| Q1 2026 | $1.18 | +49% |
| Q4 2025 | $1.04 | +39% |
| Q3 2025 | $0.94 | +31% |
| Q2 2025 | $0.85 | +47% |
| Q1 2025 | $0.79 | +58% |
| Q4 2024 | $0.75 | +67% |
ELMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ELMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7M | +11% |
| Q2 2026 | $19.4M | +12% |
| Q1 2026 | $18.6M | +18% |
| Q4 2025 | $18.9M | +16% |
| Q3 2025 | $16.9M | +15% |
| Q2 2025 | $17.4M | +17% |
| Q1 2025 | $15.7M | +13% |
| Q4 2024 | $16.3M | +19% |
ELMD's revenue has grown year over year every quarter since late 2020: $19M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2.9 points |
| Q2 2026 | 20% | +2.2 points |
| Q1 2026 | 20% | +6.6 points |
| Q4 2025 | 19% | +3.5 points |
| Q3 2025 | 16% | +2.6 points |
| Q2 2025 | 17% | +1.7 points |
| Q1 2025 | 14% | +0.4 points |
| Q4 2024 | 16% | -0.9 points |
ELMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ELMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ELMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $208K | +$291K |
| Q2 2026 | $2.8M | -25% |
| Q1 2026 | $3.3M | +49% |
| Q4 2025 | $2.4M | -18% |
| Q3 2025 | -$83K | -104% |
| Q2 2025 | $3.7M | -17% |
| Q1 2025 | $2.2M | +76% |
| Q4 2024 | $2.9M | -14% |
ELMD generated $9M in free cash flow over the past year, about the same as the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ELMD on cash flow, with more consistent year-over-year improvement.
ELMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +72.8K shares |
| 1 year | +0.9% | +79.7K shares |
| 3 years | -0.2% | -21.4K shares |
| 5 years | -1.4% | -123K shares |
| Available history | 0% | +2.3K shares |
ELMD has 9M diluted shares, up 0.9% from a year ago, despite $7M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.3M |
| Q2 2026 | — |
| Q1 2026 | $152,000 |
| Q4 2025 | $2.8M |
| Q3 2025 | $1M |
| Q2 2025 | $3.7M |
| Q1 2025 | $1.8M |
| Q4 2024 | — |
ELMD spent $7M buying back its own shares over the past year, up 12% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ELMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ELMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.7x | Net Cash |
ELMD has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ELMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.8 | Neutral |
| Stochastic | 7.0 | Oversold |
ELMD's weekly RSI is 36 (neutral) and its Stochastic is 7 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ELMD PE vs Healthcare Sector
| Metric | ELMD | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 1 | 29 | 28 pts below |
ELMD is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ELMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.1 | 7.8% below |
| 20 week MA | $33.2 | 25% below |
| 50 week MA | $30.7 | 19% below |
| 100 week MA | $27.5 | 9.3% below |
| 200 week MA | $20.9 | 20% above |
ELMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ELMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.57 | $9.99 | +17% |
| 2021 | $9.99 | $12.7 | +27% |
| 2022 | $12.7 | $9.89 | -22% |
| 2023 | $9.89 | $10.9 | +10% |
| 2024 | $10.9 | $29.2 | +168% |
| 2025 | $29.2 | $28.5 | -2.5% |
| 2026 YTD | $28.5 | $25.0 | -12% |
ELMD has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.